Efficacy of a polyvalent bacterial lysate in children with recurrent respiratory tract infections

Samuel Bentes Ruah, Carlos Ruah, Antje Van Aubel, Stephan Abel, Ulrich Elsasser

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Respiratory tract infections (RTIs) are the most frequent infections in humans, particularly in children. In addition to intervention, increasing interest is focusing on immunomodulatory therapy for recurrent RTIs, which indicate a reduced defense capacity of the respiratory mucosa. LW 50020, an oral immunomodulator that contains the antigens of seven bacteria common in RTIs, has reduced the number, duration, and severity of RTIs in children and adults. This 56-week placebo-controlled, double-blind study in 188 children investigated whether the efficacy of the standard schedule (immunization cycle + one booster cycle) would be enhanced by additional booster cycles. Efficacy and safety over the long term were also assessed. The rate of infection was reduced by 50% with the standard schedule and could not be further decreased by two consecutive booster cycles. With both schedules, this reduction was sustained during a 28-week treatment-free observation period that followed the 28-week treatment period. The number of adverse drug reactions was low, and all were transient, expected, and nonserious. These results confirm that LW 50020 is an effective and safe strategy for RTIs.

Original languageEnglish
Pages (from-to)151-162
Number of pages12
JournalAdvances In Therapy
Volume18
Issue number4
DOIs
Publication statusPublished - 2001

    Fingerprint

Keywords

  • Bacterial lysate
  • Lymphoid tissue
  • Mucosa-associated
  • Oral immunomodulator
  • Respiratory tract infections

Cite this